Tonix Pharmaceuticals宣布定价2000万美元注册直接发行

2025-12-29 21:02

Tonix Pharmaceuticals (TNXP) on Monday said it has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant.
The closing of the offering is expected to take place on or about December 30, 2025.
The gross proceeds of the offering will be approximately $20 million.
The company intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.
TNXP -2.95% premarket to $15.78.
Source: Press Release

More on Tonix Pharmaceuticals